Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P51654
UPID:
GPC3_HUMAN
Alternative names:
GTR2-2; Intestinal protein OCI-5; MXR7
Alternative UPACC:
P51654; C9JLE3; G3V1R0; Q2L880; Q2L882
Background:
Glypican-3, known by alternative names such as GTR2-2, Intestinal protein OCI-5, and MXR7, is a cell surface proteoglycan that plays a pivotal role in various signaling pathways. It regulates the hedgehog signaling pathway, positively influences the canonical and non-canonical Wnt signaling pathways, and modulates the effects of growth factors on renal branching morphogenesis and skeletal development.
Therapeutic significance:
Glypican-3 is implicated in Simpson-Golabi-Behmel syndrome 1, a genetic disorder characterized by pre- and postnatal overgrowth, facial dysmorphism, and various visceral and skeletal malformations. Understanding the role of Glypican-3 could open doors to potential therapeutic strategies for this syndrome and other related conditions.